{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:32Z","timestamp":1791920072770,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40265-021-01649-0","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T12:02:40Z","timestamp":1637668960000},"page":"71-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Maralixibat: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"1649_CR1","unstructured":"US FDA. LivmarliTM (maralixibat): US prescribing information. 2021. https:\/\/www.fda.gov. Accessed 22 Oct 2021."},{"key":"1649_CR2","unstructured":"Mirum Pharmaceuticals. Mirum Pharmaceuticals presents analyses from its rare liver disease programs at the EASL International Liver Congress 2021 [media release]. 2021. https:\/\/www.mirumpharma.com. Accessed 22 Oct 2021."},{"issue":"10","key":"1649_CR3","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep4.1244","volume":"2","author":"BL Shneider","year":"2018","unstructured":"Shneider BL, Spino C, Kamath BM, et al. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome. Hepatol Commun. 2018;2(10):1184\u201398.","journal-title":"Hepatol Commun"},{"issue":"1","key":"1649_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/hep.20295","volume":"40","author":"E Neimark","year":"2004","unstructured":"Neimark E, Chen F, Li X, et al. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology. 2004;40(1):149\u201356.","journal-title":"Hepatology"},{"key":"1649_CR5","unstructured":"US FDA. Corrected NDA approval. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/214662Orig1s000Corrected_ltr.pdf. Accessed 22 Oct 2021."},{"key":"1649_CR6","unstructured":"Mirum Pharmaceuticals. Mirum Pharmaceuticals announces European Medicines Agency validation of the Marketing Authorization Application for maralixibat in patients with PFIC2 [media release]. 2020. http:\/\/www.mirumpharma.com. Accessed 22 Oct 2021."},{"issue":"3","key":"1649_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep4.1305","volume":"3","author":"MJ Mayo","year":"2019","unstructured":"Mayo MJ, Pockros PJ, Jones D, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3(3):365\u201381.","journal-title":"Hepatol Commun"},{"key":"1649_CR8","unstructured":"Lumena Pharmaceuticals. Lumena Pharmaceuticals announces $23 million Series A financing. 2013. http:\/\/www.lumenapharma.com. Accessed 22 Oct 2021."},{"key":"1649_CR9","unstructured":"Shire. Shire adds to rare disease portfolio with acquisition of Lumena Pharmaceuticals, bringing late stage compounds for rare GI\/hepatic conditions [media release]. 2014. https:\/\/www.takeda.com. Accessed 22 Oct 2021."},{"key":"1649_CR10","unstructured":"Mirum Pharmaceuticals. Mirum Pharmaceuticals secures $120 million in Series A financing to develop phase 3-ready maralixibat for rare liver diseases [media release]. 2018. https:\/\/mirumpharma.com. Accessed 22 Oct 2021."},{"key":"1649_CR11","unstructured":"Mirum Pharmaceuticals. Mirum Pharmaceuticals announces partnership with EVERSANA to support launch and commercialization of maralixibat for Alagille syndrome in the United States [media release]. 2020. https:\/\/mirumpharma.com. Accessed 22 Oct 2021."},{"key":"1649_CR12","unstructured":"Mirum Pharmaceuticals. Mirum Pharmaceuticals and CANbridge Pharmaceuticals enter into exclusive licensing agreement to develop and commercialize maralixibat in Greater China for rare liver diseases [media release]. 2021. https:\/\/mirumpharma.com. Accessed 22 Oct 2021."},{"key":"1649_CR13","unstructured":"Mirum Pharmaceuticals. Mirum Pharmaceuticals and GC Pharma enter into exclusive licensing agreement to develop and commercialize maralixibat for rare liver diseases in South Korea [media release]. 2021. https:\/\/mirumpharma.com. Accessed 22 Oct 2021."},{"key":"1649_CR14","unstructured":"Mirum Pharmaceuticals. Mirum Pharmaceuticals and Takeda enter into exclusive licensing agreement to develop and commercialize maralixibat for rare pediatric liver diseases in Japan [media release]. 2021. https:\/\/mirumpharma.com. Accessed 22 Oct 2021."},{"issue":"10311","key":"1649_CR15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","volume":"398","author":"E Gonzales","year":"2021","unstructured":"Gonzales E, Hardikar W, Stormon M, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021;398(10311):1581\u201392.","journal-title":"Lancet"},{"issue":"6","key":"1649_CR16","first-page":"1255A","volume":"66","author":"A Baker","year":"2017","unstructured":"Baker A, Kelly DA, Gu J, et al. A long-term phase 2 safety and efficacy study of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille syndrome: preliminary results from the IMAGINE study. Hepatology. 2017;66(6):1255A-6A.","journal-title":"Hepatology"},{"key":"1649_CR17","unstructured":"Shneider BL, Spino C, Kamath BM, et al. Preliminary analysis of ITCH and IMAGINE II\u2014outcome of long-term administration of maralixibat in children with Alagille syndrome [abstract no. L05]. In: The Liver Meeting (AASLD). 2020."},{"key":"1649_CR18","unstructured":"Hansen BE, Vandriel SM, Vig P, et al. Application of real-world evidence analytics: a 6-year event-free survival analysis in Alagille syndrome of the GALA clinical research database and maralixibat treated patients [abstract no. LO7]. In: The Liver Meeting (AASLD). 2021."},{"issue":"Suppl 1","key":"1649_CR19","first-page":"783","volume":"72","author":"R Thompson","year":"2021","unstructured":"Thompson R, Kelly D, Miethke A, et al. Serum bile acid control in long-term maralixibat-treated patients is associated with native liver survival in children with progressive familial intrahepatic cholestasis due to bile salt export pump deficiency. J Pediatr Gastroenterol Nutr. 2021;72(Suppl 1):783\u20134.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl 1","key":"1649_CR20","first-page":"56A","volume":"70","author":"RJ Thompson","year":"2019","unstructured":"Thompson RJ, Jaecklin T, Peetz C, et al. Genotype and dose-dependent response to maralixibat in patients with bile salt export pump deficiency. Hepatology. 2019;70(Suppl 1):56A.","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"1649_CR21","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/S0618-8278(19)30232-4","volume":"70","author":"R Thompson","year":"2019","unstructured":"Thompson R, Kelly D, Rajwal S, et al. Growth analysis in children with progressive familial intrahepatic cholestasis treated with the apical sodium-dependent bile acid transporter inhibitor maralixibat. J Hepatol. 2019;70(1 Suppl):e131\u20132.","journal-title":"J Hepatol"},{"key":"1649_CR22","unstructured":"Raman RK, Garner W, Vig P, et al. An integrated analysis of long-term clinical safety in maralixibat-treated participants with Alagille syndrome [abstract no. P0-1285 plus poster]. In: EASL International Liver Congress. 2021."},{"issue":"Suppl 1","key":"1649_CR23","first-page":"868","volume":"72","author":"BM Kamath","year":"2021","unstructured":"Kamath BM, Raman RK, Garner W, et al. Gastrointestinal tolerability of maralixibat in patients with Alagille syndrome: an integrated analysis of short-and long-term treatment. J Pediatr Gastroenterol Nutr. 2021;72(Suppl 1):868.","journal-title":"J Pediatr Gastroenterol Nutr"}],"updated-by":[{"DOI":"10.1007\/s40265-021-01659-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01649-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01649-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01649-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T10:38:50Z","timestamp":1641811130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01649-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1649"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01649-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"assertion":[{"value":"23 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01659-y","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01659-y","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}